Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report)’s share price was down 1.7% on Tuesday . The company traded as low as $1.58 and last traded at $1.76. Approximately 20,514 shares changed hands during mid-day trading, a decline of 16% from the average daily volume of 24,454 shares. The stock had previously closed at $1.79.
Humacyte Price Performance
The company’s 50 day simple moving average is $1.70 and its 200-day simple moving average is $1.95.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Articles
- Five stocks we like better than Humacyte
- Profitably Trade Stocks at 52-Week Highs
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
